Myeloma 2018 | Is precision medicine a bust in myeloma?

Dirk Hose, Faith Davies, Jeffrey Wolf and Rafael Fonseca

In this exciting discussion, the experts explore the prevocative question of ‘is precision medicine a bust in multiple myeloma?’ Topics discussed include the limitations and future potential of precision medicine, the impact of 1q copy number on prognosis and the level of BRAF mutation needed for response to inhibitors. Rafael Fonesca, MD, of the Mayo Clinic, Phoenix, AZ, chairs this discussion with Dirk Hose, MD, of University Hospital Heidelberg, Heidelberg, Germany, Faith Davies, MD, MRCP, MRCPath, FRCPath, of UAMS Myeloma Institute, Little Rock, AR, and Jeffrey Wolf, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, at the Myeloma 2018 meeting held in San Diego, CA.

Share this video